SNGX Stock Catalyst: Soligenix Reports Positive Patient Responses to HyBryte Therapy

Soligenix announced Soligenix reports positive patient responses to HyBryte therapy, with over 70% achieving 'Treatment Success' in a study supported by a $2.6 million FDA Orphan Products Development Grant.

5 of the 6 subjects. The announcement cited $2.6 million, and over 70%.

SOLIGENIX, INC. has a free float of 9,362,300 shares and 10,086,100 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.